Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1187 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7812.042 | 1.0750 | 1.1544 | 0.9722 | |
| HCC1187 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7812.042 | 1.1231 | 1.2536 | 0.9722 | |
| HCC1187 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7812.042 | 1.0616 | 1.1269 | 0.9722 | |
| HCC1187 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7812.042 | 1.0421 | 1.0867 | 0.9722 | |
| HCC1187 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7812.042 | 1.1019 | 1.2099 | 0.9722 | |
| HCC1187 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7812.042 | 1.0363 | 1.0748 | 0.9722 | |
| HCC1187 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7812.042 | 0.9637 | 0.9253 | 0.9722 | |
| HCC1187 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.137 | uM | 7812.042 | 0.7861 | 0.5614 | 0.9722 | |
| HCC1187 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.685 | uM | 7812.042 | 1.0319 | 1.0657 | 0.9722 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7813.018 | 1.1093 | 1.2623 | 0.8420 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7813.018 | 0.9325 | 0.8407 | 0.8420 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7813.018 | 1.1505 | 1.3624 | 0.8420 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7813.018 | 1.0742 | 1.1776 | 0.8420 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7813.018 | 1.2113 | 1.5113 | 0.8420 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7813.018 | 1.1856 | 1.4482 | 0.8420 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7813.018 | 0.9858 | 0.9664 | 0.8420 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.137 | uM | 7813.018 | 1.1546 | 1.3723 | 0.8420 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.685 | uM | 7813.018 | 0.8805 | 0.7195 | 0.8420 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7814.042 | 1.0094 | 1.0224 | 0.8414 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7814.042 | 1.0451 | 1.1077 | 0.8414 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7814.042 | 1.0140 | 1.0333 | 0.8414 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7814.042 | 0.9809 | 0.9547 | 0.8414 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7814.042 | 1.0385 | 1.0919 | 0.8414 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7814.042 | 1.0085 | 1.0203 | 0.8414 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7814.042 | 0.9646 | 0.9161 | 0.8414 |